These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 34418758)

  • 1. Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.
    Cobos-Campos R; Apiñaniz A; Parraza N; Cordero J; García S; Orruño E
    Curr Res Transl Med; 2021 Oct; 69(4):103309. PubMed ID: 34418758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial.
    Wijewickrema A; Banneheke H; Pathmeswaran A; Refai FW; Kauranaratne M; Malavige N; Jeewandara C; Ekanayake M; Samaraweera D; Thambavita D; Galappatthy P
    BMC Infect Dis; 2024 Jul; 24(1):719. PubMed ID: 39039459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.
    Shirazi FM; Mirzaei R; Nakhaee S; Nejatian A; Ghafari S; Mehrpour O
    Eur J Med Res; 2022 Feb; 27(1):21. PubMed ID: 35123559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
    Rakedzon S; Neuberger A; Domb AJ; Petersiel N; Schwartz E
    J Travel Med; 2021 Feb; 28(2):. PubMed ID: 33480414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants.
    Hernandez AV; Liu A; Roman YM; Burela PA; Pasupuleti V; Thota P; Carranza-Tamayo CO; Retamozo-Palacios M; Benites-Zapata VA; Piscoya A; Vidal JE
    Int J Antimicrob Agents; 2024 Aug; 64(2):107248. PubMed ID: 38908535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
    Formiga FR; Leblanc R; de Souza Rebouças J; Farias LP; de Oliveira RN; Pena L
    J Control Release; 2021 Jan; 329():758-761. PubMed ID: 33038449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
    Kory P; Meduri GU; Varon J; Iglesias J; Marik PE
    Am J Ther; 2021 Apr; 28(3):e299-e318. PubMed ID: 34375047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.
    Low ZY; Yip AJW; Lal SK
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
    Kinobe RT; Owens L
    Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Gentile N; Collins S; McCarthy MW; Jayaweera D; Castro M; Sulkowski M; McTigue K; Thicklin F; Felker GM; Ginde AA; Bramante CT; Slandzicki AJ; Gabriel A; Shah NS; Lenert LA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Wilder R; Wilson S; Shenkman E; Hernandez AF;
    JAMA; 2022 Oct; 328(16):1595-1603. PubMed ID: 36269852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
    Buonfrate D; Chesini F; Martini D; Roncaglioni MC; Ojeda Fernandez ML; Alvisi MF; De Simone I; Rulli E; Nobili A; Casalini G; Antinori S; Gobbi M; Campoli C; Deiana M; Pomari E; Lunardi G; Tessari R; Bisoffi Z
    Int J Antimicrob Agents; 2022 Feb; 59(2):106516. PubMed ID: 34999239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.
    Bryant A; Lawrie TA; Dowswell T; Fordham EJ; Mitchell S; Hill SR; Tham TC
    Am J Ther; 2021 Jun; 28(4):e434-e460. PubMed ID: 34145166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
    Wehbe Z; Wehbe M; Iratni R; Pintus G; Zaraket H; Yassine HM; Eid AH
    Front Immunol; 2021; 12():663586. PubMed ID: 33859652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature.
    Chaudhry MW; Zubair SM; Zubairi ABS; Irfan M
    Adv Respir Med; 2021; 89(4):413-418. PubMed ID: 34494244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Medina MF; Achinelli F; Guglielmone HA; Ojeda J; Farizano Salazar D; Andino G; Kawerin P; Dellamea S; Aquino AC; Flores V; Martemucci CN; Martinez SM; Segovia JE; Reynoso PI; Sosa NC; Robledo ME; Guarrochena JM; Vernengo MM; Ruiz Diaz N; Meza E; Aguirre MG
    BMC Infect Dis; 2021 Jul; 21(1):635. PubMed ID: 34215210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.